DOSING REGIMENS FOR ORAL ALK2 KINASE INHIBITORS
Disclosed are dosage forms of compounds and pharmaceutically acceptable salts thereof, which are inhibitors of ALK2 kinase, including mutant forms of ALK2. Also disclosed are methods of using the oral dosage forms in the treatment or prevention of a disease or condition whose treatment would benefit...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | SHERIDAN, WILLIAM P BABU, YARLAGADDA S |
| description | Disclosed are dosage forms of compounds and pharmaceutically acceptable salts thereof, which are inhibitors of ALK2 kinase, including mutant forms of ALK2. Also disclosed are methods of using the oral dosage forms in the treatment or prevention of a disease or condition whose treatment would benefit from ALK2 kinase inhibition (e.g., Fibrodysplasia Ossificans Progressiva and cancer).
Des formes médicamenteuses de composés et des sels pharmaceutiquement acceptables de ceux-ci, qui sont des inhibiteurs de la kinase ALK2, y compris des formes mutantes d'ALK2, sont divulgués. Des procédés d'utilisation des formes posologiques orales dans le traitement ou la prévention d'une maladie ou d'un état dont le traitement bénéficierait de l'inhibition de la kinase ALK2 (par exemple, la fibrodysplasie ossifiante progressive et le cancer) sont également divulgués. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA3205111A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA3205111A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA3205111A13</originalsourceid><addsrcrecordid>eNrjZNB38Q_29HNXCHJ19_R19QtWcPMPUvAPcvRRcPTxNlLw9vRzDHZV8PTz8HTyDPEPCuZhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfHOjsZGBqaGhoaOhsZEKAEAoH4lKQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>DOSING REGIMENS FOR ORAL ALK2 KINASE INHIBITORS</title><source>esp@cenet</source><creator>SHERIDAN, WILLIAM P ; BABU, YARLAGADDA S</creator><creatorcontrib>SHERIDAN, WILLIAM P ; BABU, YARLAGADDA S</creatorcontrib><description>Disclosed are dosage forms of compounds and pharmaceutically acceptable salts thereof, which are inhibitors of ALK2 kinase, including mutant forms of ALK2. Also disclosed are methods of using the oral dosage forms in the treatment or prevention of a disease or condition whose treatment would benefit from ALK2 kinase inhibition (e.g., Fibrodysplasia Ossificans Progressiva and cancer).
Des formes médicamenteuses de composés et des sels pharmaceutiquement acceptables de ceux-ci, qui sont des inhibiteurs de la kinase ALK2, y compris des formes mutantes d'ALK2, sont divulgués. Des procédés d'utilisation des formes posologiques orales dans le traitement ou la prévention d'une maladie ou d'un état dont le traitement bénéficierait de l'inhibition de la kinase ALK2 (par exemple, la fibrodysplasie ossifiante progressive et le cancer) sont également divulgués.</description><language>eng ; fre</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220630&DB=EPODOC&CC=CA&NR=3205111A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25569,76552</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220630&DB=EPODOC&CC=CA&NR=3205111A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SHERIDAN, WILLIAM P</creatorcontrib><creatorcontrib>BABU, YARLAGADDA S</creatorcontrib><title>DOSING REGIMENS FOR ORAL ALK2 KINASE INHIBITORS</title><description>Disclosed are dosage forms of compounds and pharmaceutically acceptable salts thereof, which are inhibitors of ALK2 kinase, including mutant forms of ALK2. Also disclosed are methods of using the oral dosage forms in the treatment or prevention of a disease or condition whose treatment would benefit from ALK2 kinase inhibition (e.g., Fibrodysplasia Ossificans Progressiva and cancer).
Des formes médicamenteuses de composés et des sels pharmaceutiquement acceptables de ceux-ci, qui sont des inhibiteurs de la kinase ALK2, y compris des formes mutantes d'ALK2, sont divulgués. Des procédés d'utilisation des formes posologiques orales dans le traitement ou la prévention d'une maladie ou d'un état dont le traitement bénéficierait de l'inhibition de la kinase ALK2 (par exemple, la fibrodysplasie ossifiante progressive et le cancer) sont également divulgués.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNB38Q_29HNXCHJ19_R19QtWcPMPUvAPcvRRcPTxNlLw9vRzDHZV8PTz8HTyDPEPCuZhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfHOjsZGBqaGhoaOhsZEKAEAoH4lKQ</recordid><startdate>20220630</startdate><enddate>20220630</enddate><creator>SHERIDAN, WILLIAM P</creator><creator>BABU, YARLAGADDA S</creator><scope>EVB</scope></search><sort><creationdate>20220630</creationdate><title>DOSING REGIMENS FOR ORAL ALK2 KINASE INHIBITORS</title><author>SHERIDAN, WILLIAM P ; BABU, YARLAGADDA S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA3205111A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2022</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SHERIDAN, WILLIAM P</creatorcontrib><creatorcontrib>BABU, YARLAGADDA S</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SHERIDAN, WILLIAM P</au><au>BABU, YARLAGADDA S</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>DOSING REGIMENS FOR ORAL ALK2 KINASE INHIBITORS</title><date>2022-06-30</date><risdate>2022</risdate><abstract>Disclosed are dosage forms of compounds and pharmaceutically acceptable salts thereof, which are inhibitors of ALK2 kinase, including mutant forms of ALK2. Also disclosed are methods of using the oral dosage forms in the treatment or prevention of a disease or condition whose treatment would benefit from ALK2 kinase inhibition (e.g., Fibrodysplasia Ossificans Progressiva and cancer).
Des formes médicamenteuses de composés et des sels pharmaceutiquement acceptables de ceux-ci, qui sont des inhibiteurs de la kinase ALK2, y compris des formes mutantes d'ALK2, sont divulgués. Des procédés d'utilisation des formes posologiques orales dans le traitement ou la prévention d'une maladie ou d'un état dont le traitement bénéficierait de l'inhibition de la kinase ALK2 (par exemple, la fibrodysplasie ossifiante progressive et le cancer) sont également divulgués.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA3205111A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | DOSING REGIMENS FOR ORAL ALK2 KINASE INHIBITORS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T18%3A30%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SHERIDAN,%20WILLIAM%20P&rft.date=2022-06-30&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA3205111A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |